TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01632345
Drug: Efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz 600 mg tablet orally at bedtime taken without food on an empty stomach for 96 weeks
Study: NCT01632345
Drug: Placebo for Doravirine
DrugBank: Doravirine (DB12301)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Placebo tablets matching doravirine
Study: NCT01632345
Drug: Placebo for Efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo tablets matching efavirenz
Study: NCT03049189
Drug: 177Lu-edotreotide PRRT
Normalized name: edotreotride
DrugBank: Edotreotide (DB17969)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRRT using 177Lu-edotreotide will be performed 3-monthly. A maximum of four cycles will be administered.
Study: NCT03049189
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus will be adminstered as a standard dosis of 10 mg daily which may be reduced where required for acceptable tolerability.
Study: NCT01916733
Drug: standard insulin protocol post-op (continuous IV insulin)
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: concurrent, matched cohort study of moderate postoperative glucose control in patients undergoing LEB or open AAA repair.Propensity score matching is a statistical method used to reduce the confounding effects of covariates in an observational (non-randomized) study. In practice we will select a number of variables that impact wound infection; age, gender, diabetic and non-diabetic populations, renal insufficiency (defined at creatinine ≥1.8) and indication for surgery (claudication or critical limb ischemia with rest pain or tissue loss or open AAA repair); and chose a group of patients in the Vascular Study Group matched for these variables who have not been treated with an insulin infusion). Consecutive patients undergoing elective open AAA repair or infrainguinal LEB for claudication and critical limb ischemia will be invited to enroll in the study.
Study: NCT01724021
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard chemotherapy
Study: NCT01724021
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1400 mg subcutaneously (SC), Day 1 Cycles 2-4
Study: NCT01724021
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m2 IV, Day 1 Cycles 1-4
Study: NCT01724021
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m2 intravenously (IV), Day 1 Cycles 1 and 4-8
Study: NCT01724021
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1400 mg SC, Day 1 Cycles 5-8
Study: NCT03217266
Drug: Navtemadlin
Normalized name: Navtemadlin
DrugBank: Navtemadlin (DB15299)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT03023436
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CF regimens or other first line regimens based on Fluoropyrimidine and Platinum according to the NCCN Guidelines（Gastric Cancer，version 3.2016) are recommended.Regimens and dosing schedules are not limited in this trial.
Study: NCT00977691
Drug: Alemtuzumab
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: alemtuzumab
Study: NCT00977691
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: sirolimus
Study: NCT01903811
Drug: Carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02864394
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel administered IV at 75 mg/m\^2 on Day 1 of each 21-day cycle as per the approved product label.
Study: NCT01903811
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04034225
Drug: SNS-301
Normalized name: sn-3-GPC
DrugBank: Choline alfoscerate (DB04660)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 0, Week 3, Week 6, Week 9 then every 6 weeks (±3 days) for 6 additional doses, thereafter every 12 weeks (±3 days) up to 24 months.
Study: NCT04034225
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab (200 mg dose) IV infusion will be administered over 30 minutes every 3 weeks up to 24 months or Pembrolizumab (400 mg dose) IV will be administered over 30 minutes every 6 weeks up to 24 months.
Study: NCT03067701
Drug: Carbon Monoxide
Normalized name: carbon monoxide
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In healthy young adults 18-39 years of age, The investigator will determine if intermittent inhalation of 0.1% CO, from a 1-Liter bag once every minute for 30-40 min at a level that approaches the CO boost with hookah smoking, augments endothelial function.
Study: NCT01738672
Drug: Inhaled nitrous oxide
Normalized name: nitrous oxide Inhalant Product
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of nitrous oxide for labor analgesia
Study: NCT02094339
Drug: ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.2% ropivacaine
Study: NCT03917394
Drug: rHuEPO
Normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEPO was administrated daily with 10000 IU or 20000 IU
Study: NCT03917394
Drug: Iron sucrose
Normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron sucrose was administrated daily with 100mg or 200mg
Study: NCT02429076
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled anesthetic
Study: NCT02429076
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV anesthetic
Study: NCT01990339
Drug: Lansoprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: • Reflux esophagitis The usual adult dosage is 30 mg of lansoprazole administered orally once daily for up to 8 weeks.~For maintenance therapy of repeatedly recurring/relapsing reflux esophagitis, the dosage is 15 mg of lansoprazole administered orally once daily. If insufficient efficacy is observed, the dosage may be increased to 30 mg administered orally once daily.~• Nonerosive gastroesophageal reflux disease Non-erosive gastroesophageal reflux disease The usual adult dosage is 15 mg of lansoprazole administered orally once daily for up to 4 weeks.
Study: NCT00529152
Drug: Deferiprone
Normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ferriprox (deferiprone) oral solution will be given orally at a total daily dose of 75 mg/kg body weight or 100 mg/kg body weight, divided into 3 doses, for 24 weeks.
Study: NCT01741285
Drug: Beclomethasone (QVAR)
Normalized name: beclomethasone Metered Dose Inhaler [Qvar]
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small particle treatment
Study: NCT01741285
Drug: Beclomethasone (Clenil)
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Course particle beclomethasone
Study: NCT01741285
Drug: Fluticasone
Normalized name: Fluticasone
DrugBank: Fluticasone (DB13867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Course particle treatment
Study: NCT04330586
Drug: Ciclesonide Metered Dose Inhaler [Alvesco]
Normalized name: ciclesonide Metered Dose Inhaler [Alvesco]
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclesonide 320ug oral inhalation q12h for 14 days
Study: NCT02289144
Drug: Ceritinib
Normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 750 mg orally daily on day 1. Continue every 4 weeks and every 2 cycles (1 Cycle is 28 days long) : until progression, new recurrence or distant metastasis, as well as enlargment of an existing metastasis on radiological Imaging.
Study: NCT00979576
Drug: BIBF 1120 H + Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BIBF 1120 high dose bid+ Pemetrexed 500 mg/m\^2
Study: NCT00352794
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral 10 mg daily/days 1-21 of 28 day cycle
Study: NCT00352794
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting dose oral 30 mg/day during cycle 1, 15 mg/day during cycle 2, and 15 mg every other day during cycle 3, and then it will be discontinued.
Study: NCT03949894
Drug: Tolvaptan
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 30mg and 15mg of Tolvaptan Tablet
Study: NCT00979576
Drug: BIBF 1120 RD + Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: confirmed dose of BIBF 1120 bid + Pemetrexed 500 mg/m\^2
Study: NCT00979576
Drug: BIBF 1120 L + Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BIBF 1120 low dose bid+ Pemetrexed 500 mg/m\^2
Study: NCT00979576
Drug: BIBF 1120 Placebo + Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: placebo BIBF 1120 bid + Pemetrexed 500 mg/m\^2
Study: NCT06745856
Drug: 5-fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subconjunctival, peroperative, application of 50mg/ml concentration of 5-fluoruracil.
Study: NCT02774499
Drug: Methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.3mg/kg of methadone given preoperatively (to maximum of 30mg)
Study: NCT00286234
Drug: extended release niacin
Normalized name: niacin Extended Release Oral Capsule
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g qpm
Study: NCT04194086
Drug: posaconazole oral suspensions
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: posaconazole oral suspensions（5mg/kg/d,tid) will be administered specially febrile neutropenia patients four times a day and blood samples will be taken any hours after the first dose at least Day 7.
Study: NCT03026556
Drug: Dabigatran vs. Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: observed for 6 years
Study: NCT03026556
Drug: Dabigatran vs. Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Observed for 6 years
Study: NCT03040180
Drug: Electrochemotherapy with bleomycin
DrugBank: Bleomycin (DB00290)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic injection, once only treatment
Study: NCT01634087
Drug: Itacitinib
Normalized name: itacitinib
DrugBank: Itacitinib (DB12154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itacitinib administered orally
Study: NCT04386967
Drug: Keytruda
Normalized name: Keytruda
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-PD-1 antibody
Study: NCT04084210
Drug: Active Nicotine Patch
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active nicotine patches, with dosing based on the package insert (\>10 cigs/day = 21 mg patch and \<11 cigs/day = 14 mg patches).
Study: NCT00002625
Drug: topotecan hydrochloride
Normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04306627
Drug: Perindopril/Amlodipine and Perindopril/Amlodipine/Atorvastatin treatment
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: comparative antihypertensive antilipidemic treatment assessment on carotid intima media thickness in both study groups
Study: NCT02865668
Drug: Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive 1 XR FDC tablet containing canagliflozin 50 mg and metformin 500 mg orally under fed (Treatment B) or fasted (Treatment D) condition in a given treatment period as per treatment sequence.
Study: NCT02865668
Drug: Canagliflozin
Normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive canagliflozin 50 mg oral tablet) under fed (part of treatment A) or fasted (part of treatment C) condition in a given treatment period as per treatment sequence.
Study: NCT02865668
Drug: Metformin Extended Release (XR)
Normalized name: metformin Extended Release Suspension
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive 1 metformin XR tablet of 500 mg orally under fed (part of treatment A) or fasted (part of treatment C) condition in a given treatment period as per treatment sequence.
Study: NCT03710395
Drug: Nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic hypertensive breastfeeding women will be treated with slow-release 20 mg nifedipine, twice a day.
Study: NCT01639846
Drug: Vehicle for RX-10045 arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vehicle of RX-10045 Ophthalmic Solution At Visits 3A and 4, a trained study technician will instill one drop of the assigned, masked study treatment, into each eye.
Study: NCT00160147
Drug: bifeprunox
Normalized name: Bifeprunox
DrugBank: Bifeprunox (DB04888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One week titration with dose adjustments
Study: NCT01579994
Drug: Ganetespib (STA-9090) and crizotinib
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ganetespib (STA-9090) is given intravenously (days 1 and 8 of a 21 day cycle). Crizotinib will be given at the FDA approved dose of 250mg orally twice daily in a continuous fashion.
Study: NCT03284931
Drug: SAGE-217 high dose
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: high dose
Study: NCT03284931
Drug: SAGE-217 low dose
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: low dose
Study: NCT04662710
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 130 mg/m\^2 administered by IV infusion on Day 1 of Weeks 1 and 4 of each Q6W cycle as part of CAPOX chemotherapy, or 85 mg/m\^2 administered by IV infusion on Day 1 and Week 1, 3 and 5 of each Q6W cycle as part of mFOLFOX6 chemotherapy.
Study: NCT04662710
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m\^2 bolus IV infusion followed by 2400 mg/m\^2 continuous IV infusion administered on Day 1, and Week 1, 3, 5, of each Q2W cycle as part of mFOLFOX6 chemotherapy.
Study: NCT03658031
Drug: Dapagliflozin 10mg
Normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin 10 mg administered each morning before breakfast
Study: NCT03145584
Drug: Continuous Bupivacaine via Adductor Canal Saphenous Catheter
Normalized name: Uniphyllin Continus
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12.5 mg/hr of bupivacaine was administered continuously via a paraneural catheter for 48 hours following surgery to determine whether superior analgesia was obtained when compared to single shot block with a sham catheter.
Study: NCT03494504
Drug: Reproxalap Ophthalmic Solution (0.25%)
Normalized name: Reproxalap
DrugBank: Reproxalap (DB16688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reproxalap Ophthalmic Solution (0.25%) administered once.
Study: NCT03494504
Drug: Reproxalap Ophthalmic Solution (0.5%)
Normalized name: Reproxalap
DrugBank: Reproxalap (DB16688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reproxalap Ophthalmic Solution (0.5%) administered once.
Study: NCT03494504
Drug: Vehicle Ophthalmic Solution
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Ophthalmic Solution administered once.
Study: NCT03719924
Drug: Onivyde
Normalized name: Onivyde
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: onivyde will be administered first, followed by folinic acid or L-folinic acid and then 5-FU at D1 and D14.
Study: NCT03719924
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel : 80 mg/m2 IV during 60 minutes at D1, D8 and D15
Study: NCT04630808
Drug: Latanoprost 0.005%
Normalized name: LATANOPROST 0.005% SOLN,OPH
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Latanoprost Ophthalmic Solution, 0.005%
Study: NCT02761486
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 325mg aspirin per day
Study: NCT00427089
Drug: Sodium Phosphate solution (NaP)
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 45 ml solution; BID
Study: NCT00626210
Drug: modafinil
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100-400 mg daily for 4 weeks
Study: NCT03750383
Drug: EDP-938
Normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
DrugBank: Indigofera tinctoria leaf (DB14314)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive EDP-938 once daily on Day 1 and Day 5 (Part 1)
Study: NCT03750383
Drug: EDP-938
Normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
DrugBank: Indigofera tinctoria leaf (DB14314)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive one dose of EDP-938 on Day 1 and Day 8 (Part 2)
Study: NCT03750383
Drug: Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive one dose of cyclosporine on Day 5
Study: NCT03750383
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive prednisone once daily from Day 5 to Day 14
Study: NCT00448435
Drug: GW815SF HFA MDI
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: salmeterol and fluticasone propionate combination
Study: NCT00448435
Drug: salmeterol and fluticasone propionate
Normalized name: salmeterol and fluticasone
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: salmeterol + fluticasone propionate
Study: NCT01521819
Drug: Lucentis
Normalized name: Lucentis
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal injection of Lucentis as needed.
Study: NCT00021450
Drug: bicalutamide
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00021450
Drug: goserelin acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01922479
Drug: Ferric Carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg intravenous Ferric Carboxymaltose, given as undiluted slow bolus injection over 15 minutes. Allowed to take concomitant oral iron supplements in usual clinical doses as prescribed clinically by attending physicians.
Study: NCT02790957
Drug: Plerixafor
Normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single injection of 0.24 mg/kg Plerixafor
Study: NCT03417518
Drug: Desflurane Inhalant Product
Normalized name: desflurane Inhalant Product
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: General anesthesia will be induced with sufentanyl (0.2µg/kg) and thiopental (5mg/kg) and maintained by desflurane
Study: NCT03417518
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: General anesthesia will be induced with propofol (2mg/kg) and sufentanyl (0.2µg/kg) and maintained by propofol in a target-controlled infusion mode
Study: NCT01421693
Drug: Ceftriaxone
Normalized name: Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * ≥2-\<14 years - 60mg/kg/ once daily for 7 days~* 14 years and older - 2g once daily for 7 days~* Intravenous infusion. Vials of crystalline powder.
Study: NCT01421693
Drug: Gatifloxacin
Normalized name: Gatifloxacin
DrugBank: Gatifloxacin (DB01044)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gatifloxacin 10 mg/kg/day for 7 days. Tablets for oral administration.
Study: NCT04557189
Drug: TAK-951
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-951 SC injection
Study: NCT04557189
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron IV injection
Study: NCT04557189
Drug: Ondansetron Placebo
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron placebo-matching IV injection
Study: NCT00497601
Drug: Amphotericin B fat emulsion in visceral leishmaniasis
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B in fat emulsion (Amphomul) 7.5 mg/kg on day 1 \& 3 in group A Amphotericin B in fat emulsion (Amphomul) 10 \& 5 mg/kg on day 1 \& 3 in group B Amphotericin B in fat emulsion (Amphomul) 12.5 \& 2.5 mg/kg on day 1 \& 3 in group C Amphotericin B in fat emulsion (Amphomul) 15 mg/kg on day 1 in group D
Study: NCT00497601
Drug: Amphotericin B fat emulsion
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting with 7.5 mg/kg on day 1 and 3, 10 and 5 mg/kg on day 1 and 3, 12.5 and 2.5 mg/kg on day 1 and 3 and finally 15 mg/kg on day 1